Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus platinum-doublet chemotherapy and adaptive radiotherapy for unresectable stage III NSCLC
ChiCTR2600133004Phase 2Recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Progression-free survival. Started Jul 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600133004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133004.